Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

The Week In China: Simcere Pharma Files for American IPO

publication date: Mar 26, 2007
Developments In East-West Pharma Simcere Pharma, which makes generic drugs for the Chinese market, filed for an IPO that could raise up to $120 million. The company intends to list shares on the NYSE under the symbol SCR. In 2006, Simcere earned a profit of $22 million on $122 million of revenue. Compared to the prior year, profits rose almost 70% on a 25% increase in revenue. The company makes 35 pharmaceutical products at the moment, though it has approval to manufacture 100 other products. More details...


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital